Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection.
The azacitidine (Vidaza®) product monograph indicates that doses greater than 4 ml should be divided equally into two syringes and injected into different sites. Although 2 ml is a more commonly used maximum volume for subcutaneous injections, there is a lack of evidence to support the use of any given maximum volume with azacitidine. Applying the status quo of 2 ml to azacitidine results in patients receiving 3-4 injections per visit. This prospective study evaluated the frequency and type of injection site reactions when the maximum subcutaneous injection volume was increased from 2 to 3 ml per injection site. Among 30 patients, 309 doses were administered, and injection site reactions were noted in 92.9% of all doses, with the majority (82.2%) being grade 1; only 10.7% of doses resulted in grade 2 reactions, and there were no grade 3 or 4 reactions. There was no increase in frequency or severity of injection site reactions when the maximum volume was increased to 3 ml. The median number of injections that patients received per visit decreased from 3 to 2 after the volume was increased, and there was a statistically significant reduction in the incidence of pain. Decreasing the number of injections also facilitates ease of rotation of injection sites and decreases pharmacy preparation time. This is the first time that injection site reaction data relating to injection volume have been reported for azacitidine.
['Ferruccio|Lauren F|LF|', 'Murray|Cindy|C|', 'Yee|Karen W|KW|', 'Incekol|Diana|D|', 'Lee|Roy|R|', 'Paisley|Emma|E|', 'Ng|Pamela|P|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000964:Antimetabolites, Antineoplastic D001374:Azacitidine D005260:Female D006801:Humans D007279:Injections, Subcutaneous D008297:Male D008875:Middle Aged D009369:Neoplasms D011446:Prospective Studies D013594:Syringes
azacitidine Subcutaneous maximum volume 3 ml injection injection site reaction